Quantifying the Survival Benefit of HLA-Incompatible Kidney Transplantation: A Multi-Center Study
Surgery, Hopkins, Baltimore, MD.
Meeting: 2015 American Transplant Congress
Abstract number: 193
Keywords: Alloantibodies, Highly-sensitized, Kidney transplantation, Multicenter studies
Session Information
Session Name: Concurrent Session: Kidney: Desensitization
Session Type: Concurrent Session
Date: Monday, May 4, 2015
Session Time: 2:15pm-3:45pm
Presentation Time: 2:27pm-2:39pm
Location: Terrace I-III
A single center study has demonstrated a two-fold survival benefit of incompatible live donor kidney transplant (ILDKT) compared to remaining on dialysis. We sought to validate these findings using data from a 22-center cohort of ILDKT patients (n=1025;185 positive Luminex, negative flow [PLNF],536 positive flow, negative cytotoxic [PFNC],304 positive complement-dependent cytotoxic crossmatch [CDC])
ILDKT (n=1025) | |||||||
Overall (n=1025) | Positive Luminex, Negative Flow Crossmatch (n=185) | Positive Flow, Negative Cytotoxic Crossmatch (n=536) | Positive Cytotoxic Crossmatch (n=304) | ||||
Mean Age | 45.0 | 45.4 | 45.5 | 43.8 | |||
Female | 67.0% | 67.6% | 68.1% | 64.8% | |||
Black | 16.4% | 17.3% | 18.7% | 11.8% | |||
Previous Transplant | 46.2% | 36.8% | 43.7% | 56.6% | |||
Median PRA (IQR) | 66 (22-94) | 51 (18-82) | 57.5 (14-93) | 85 (50-98) | |||
Diabetes Mellitus | 20.5% | 25.4% | 22.2% | 14.5% | |||
Mean Years of Dialysis | 4.5 | 3.2 | 4.1 | 5.8 | |||
Mean Donor Age | 40.7 | 41.6 | 40.5 | 40.5 |
To cite this abstract in AMA style:
Orandi B, Luo X, Massie A, Garonzik-Wang J, Lonze B, Ahmed R, Arendonk KVan, Montgomery R, Segev D. Quantifying the Survival Benefit of HLA-Incompatible Kidney Transplantation: A Multi-Center Study [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/quantifying-the-survival-benefit-of-hla-incompatible-kidney-transplantation-a-multi-center-study/. Accessed October 6, 2024.« Back to 2015 American Transplant Congress